Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737512 · ClinicalTrials.gov registry record · Early Phase 1
Mindfulness-Based ADHD Treatment for Children: a Feasibility Study
A Early Phase 1 study of Attention Deficit Hyperactivity Disorder, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT04737512 is a Early Phase 1 study of Attention Deficit Hyperactivity Disorder that has completed, run by Yale University. The registered enrollment target is 68 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04737512, a Early Phase 1 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
Attention-Deficit/Hyperactivity Disorder (ADHD) affects 11% of children and leads to adverse outcomes. Medications, while often effective in reducing certain ADHD symptoms, have many disadvantages, including misuse and side effects. Behavioral interventions do not have these adverse effects, but they are not as effective. Mindfulness is a candidate intervention for ADHD in elementary school children, but has not been systematically and rigorously studied. This study will evaluate the feasibility and acceptability of Mindfulness-Based ADHD Treatment for Children (MBAT-C). MBAT-C is designed for children at precisely the age when ADHD-relevant neurocognitive systems are developing and clinical symptoms begin to appear. Forty-five children from the New Haven, CT area, ages 7-13, will be recruited to participate in this randomized-controlled feasibility trial that will compare MBAT-C, medication, and a combined intervention.
Conditions Studied
Interventions
- BEHAVIORAL Mindfulness-Based ADHD Treatment for Children
- BIOLOGICAL Goal-Standard Medication (Treatment as Usual)
Study Locations (1)
Connecticut
- Clinical & Affective Neuroscience Lab - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-10-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04737512
The ClinicalTrials.gov registry entry for NCT04737512 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (67% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Mindfulness-Based ADHD Treatment for Children is the first listed.
NCT04737512 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04737512 about?
NCT04737512 is a clinical study titled "Mindfulness-Based ADHD Treatment for Children: a Feasibility Study". Attention-Deficit/Hyperactivity Disorder (ADHD) affects 11% of children and leads to adverse outcomes. Medications, while often effective in reducing certain ADHD symptoms, have many disadvantages, including misuse and side effects. Behavioral interventions do not have these adverse effects, but the...
What is the current status of trial NCT04737512?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 68 participants. The study started on 2021-02-01. Estimated completion is 2024-10-29.
What conditions does trial NCT04737512 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT04737512?
The interventions under investigation include: Mindfulness-Based ADHD Treatment for Children (BEHAVIORAL), Goal-Standard Medication (Treatment as Usual) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04737512?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04737512 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD
COMPLETED · Early Phase 1
-
Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder
COMPLETED · Early Phase 1
-
Developing Brain, Impulsivity and Compulsivity
RECRUITING
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.